Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia

Hypertension Clinical Trial

— CEPHEUS  

Official title:

Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01768403
• Other study ID #: NIS-CDZ-XXX-2012/1
• Status: Completed
• Phase: N/A
• First received: January 14, 2013
• Last updated: January 14, 2013
• Start date: September 2010
• Est. completion date: March 2011

Study information

• Verified date: January 2013
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Algeria: Ministry of Health
• Study type: Observational

Clinical Trial Summary

Centralized Pan-Algerian Survey on the undertreatment of hypercholesterolemia. The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Third Joint European Task Force guidelines in the survey population.

Description:

Centralised Pan-Algerian Survey on the undertreatment of hypercholesterolemia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1236
• Est. completion date: March 2011
• Est. primary completion date: March 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Subject must provide informed consent and comply with the survey procedures.

• Subject is on lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks.

Exclusion Criteria:

• Subjects who are unwilling or unable to provide informed consent.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Coronary Artery Disease
• Coronary Disease
• Coronary Heart Disease
• Diabetes
• Heart Diseases
• Hypercholesterolemia
• Hypertension
• Myocardial Ischemia
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force (TJETF) guidelines.		24 weeks	No
Secondary	Number and percentage of subjects achieving LDL-C goals according to the TJETF guidelines.	In the following sub-populations: - Patients with / or not with metabolic syndrome (according to NCEP III definition), - Primary/secondary prevention patients	24 weeks	No
Secondary	Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III/2004 updated NCEP ATP III and to the 2005 AFSSAPS guidelines	Overall and in the following sub-populations: Patients with/or without metabolic syndrome-Iary/IIary preven	24 weeks	No
Secondary	Number and percentage of subjects achieving LDL-C goals according to the : TJETF / NCEP ATP III and 2004 updated NCEP ATP III guidelines.	For the following sub-populations: Demographic variables, CV risk factors & Lipid-lowering agent class	24 weeks	No
Secondary	The association between achievement of LDL-C goals, according to the Third Joint European Task Force / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables, assessed by multivariate logistic regression models		24 weeks	No